A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Evacetrapib (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 02 Apr 2014 Results published in the American Journal of Cardiology.
- 26 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.